Last reviewed · How we verify
Cenicriviroc in moderate liver impaired
Cenicriviroc in moderate liver impaired is a Small molecule drug developed by Tobira Therapeutics, Inc.. It is currently in Phase 1 development. Also known as: CVC.
At a glance
| Generic name | Cenicriviroc in moderate liver impaired |
|---|---|
| Also known as | CVC |
| Sponsor | Tobira Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cenicriviroc in moderate liver impaired CI brief — competitive landscape report
- Cenicriviroc in moderate liver impaired updates RSS · CI watch RSS
- Tobira Therapeutics, Inc. portfolio CI
Frequently asked questions about Cenicriviroc in moderate liver impaired
What is Cenicriviroc in moderate liver impaired?
Cenicriviroc in moderate liver impaired is a Small molecule drug developed by Tobira Therapeutics, Inc..
Who makes Cenicriviroc in moderate liver impaired?
Cenicriviroc in moderate liver impaired is developed by Tobira Therapeutics, Inc. (see full Tobira Therapeutics, Inc. pipeline at /company/tobira-therapeutics-inc).
Is Cenicriviroc in moderate liver impaired also known as anything else?
Cenicriviroc in moderate liver impaired is also known as CVC.
What development phase is Cenicriviroc in moderate liver impaired in?
Cenicriviroc in moderate liver impaired is in Phase 1.
Related
- Manufacturer: Tobira Therapeutics, Inc. — full pipeline
- Also known as: CVC
- Compare: Cenicriviroc in moderate liver impaired vs similar drugs
- Pricing: Cenicriviroc in moderate liver impaired cost, discount & access